Morgan Stanley Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$144.95 - $152.29 $54.4 Million - $57.2 Million	375,508 Added 197.19%	565,941 $85.6 Million
Q2 2022 Oct 27, 2022	BUY	$83.14 - $145.99 $7.31 Million - $12.8 Million	87,881 Added 85.69%	190,433 $27.7 Million
Q2 2022 Aug 15, 2022	BUY	$83.14 - $145.99 $7.31 Million - $12.8 Million	87,881 Added 85.69%	190,433 $27.7 Million
Q1 2022 Oct 27, 2022	SELL	$110.08 - $142.92 $9.67 Million - $12.6 Million	-87,881 Reduced 46.15%	102,552 $12.2 Million
Q1 2022 May 13, 2022	BUY	$110.08 - $142.92 $2.2 Million - $2.85 Million	19,949 Added 24.15%	102,552 $12.2 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $4.01 Million - $5.98 Million	40,245 Added 95.01%	82,603 $11.4 Million
Q3 2021 Nov 15, 2021	BUY	$98.85 - $138.91 $4.19 Million - $5.88 Million	42,358 New	42,358 $5.88 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.